Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00247273 · ClinicalTrials.gov registry record · Phase 3
A Study of Monthly Risedronate for Osteoporosis
A Phase 3 study of Postmenopausal Osteoporosis, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,294
- Enrollment target
- 20
- Study locations
NCT00247273: Completed Phase 3 study of Postmenopausal Osteoporosis, sponsored by Warner Chilcott.
NCT00247273 is a Phase 3 study of Postmenopausal Osteoporosis that has completed, run by Warner Chilcott. The registered enrollment target is 1,294 participants, above the 428-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (202% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00247273, a Phase 3 study of Postmenopausal Osteoporosis, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,294 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
Primary Outcome
BMD assessed using dual-energy x-ray absorptiometry (DXA) using Hologic or Lunar equipment. LOCF - last observation carried forward (Last post-baseline measurement available to Month 12).
Conditions Studied
Interventions
- DRUG risedronate
Study Locations (20)
Other
- Research Site - Capital Federal
- Research Site - Geelong
- Research Site - Heidelberg, Victoria
- Research Site - Saint Leonards
- Research Site - Brussels
- Research Site - Ghent
- Research Site - Leuven
- Research Site - Liège
- Research Site - Mont Godinne
- Research Site - Rio de Janeiro
- Research Site - São Paulo
- Research Site - Calgary
Colorado
- Research Site - Lakewood
Georgia
- Research Site - Gainesville
Maryland
- Research Site - Bethesda
Nebraska
- Research Site - Omaha
New York
- Research Site - West Haverstraw
Ohio
- Research Site - Cincinnati
Oregon
- Research Site - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,294 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-04 |
| Phase | Phase 3 |
What the finished NCT00247273 record still lists
NCT00247273 is an interventional study that assigns participants to a tested intervention. Its 1,294 participants enrollment target places it among the larger protocols in the corpus, above the 428-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (202% higher).
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which risedronate is the first listed.
NCT00247273 names 20 study sites across 9 states, led by Other, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT00247273 about?
NCT00247273 is a clinical study titled "A Study of Monthly Risedronate for Osteoporosis". The purpose of this trial is to study the efficacy of a single-dose monthly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.
What is the current status of trial NCT00247273?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,294 participants. The study started on 2005-10. Estimated completion is 2008-04.
What conditions does trial NCT00247273 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT00247273?
The interventions under investigation include: risedronate (DRUG).
Who is sponsoring clinical trial NCT00247273?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00247273 being conducted?
This trial has 20 study locations across Colorado, Georgia, Maryland, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00247273's enrollment target sits among peer trials
1,294 2nd of 14 the highest of 14 other Postmenopausal Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postmenopausal Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
-
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
COMPLETED · Phase 3
-
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
COMPLETED · Phase 3
-
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
COMPLETED · Phase 3
-
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
COMPLETED · Phase 3
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05812807 · 1,295 participants · Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT05595642 · 1,290 participants · Phase 3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- NCT04474223 · 1,300 participants · Phase 3
Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ)
- NCT04792684 · 1,300 participants
Collection of Samples USOPTIVAL Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia